<DOC>
	<DOC>NCT00825019</DOC>
	<brief_summary>Primary objective is to demonstrate the antidepressant efficacy on the Hamilton depression rating scale (HAM-D) of amibegron (SR58611) 700 mg/day compared to placebo in the treatment of patients with a recurrent major depressive episode (MDD). Secondary objective is to assess the safety profile of amibegron 700 mg/d in comparison to placebo and to assess plasma concentrations of the active metabolite.</brief_summary>
	<brief_title>Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Amibegron</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>patients suffering from a recurrent major depressive episode of at least moderate intensity (DSMIV) patients have been hospitalized for the treatment of a previous episode, or a previous episode required antidepressant treatment(s)at the recommended dose level for at least 2 months. the duration of the current episode is of at least six weeks unless the severity of symptoms justifies shorter duration.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Depression</keyword>
</DOC>